[PDF] Top 20 La actividad física como determinante de la imagen y composición corporal en universitarios

... of anti-VEGF agents increases, it is important to determine the long- term outcomes that are being achieved in clinical practice throughout the ...encouraging. Anti-VEGF therapy, ... See full document

... and retrospective studies retrieved by the key terms <exu- dative> or <neovascular> and <AMD> or <age-related macular degeneration> AND <intravitreal ... See full document

... patient age was ...for treatment was bilateral exudative ARMD in all ...intravitreal anti-VEGF injection before, 57 had a his- tory of unilateral anti-VEGF injection, and 38 had ... See full document

... over 5 years. In OCT, an increase in central retinal thickness over 5 years could be ...deficient treatment when comparing the total injection number to other treatment ...regimens. ... See full document

... VA outcomes of treated nAMD patients using anti-VEGF injections at non- fi xed intervals and the average follow-up duration of those available was 6 to 7 ...for treatment, local government ’ s ... See full document

... this retrospective cohort study at a large urban tertiary medical ...of treatment- naïve patients receiving intravitreal anti-VEGF injections from four retina specialists for the diagnosis of ... See full document

... of anti- VEGF agents in terms of the stability or improvement in VA after 1 and 2 years of ...intravitreal anti-VEGF injection com- pared with control ...of anti-VEGF ... See full document

... Patients in this study were on anti-VEGF therapy and the great majority of them had good visual acuity and did not have visual impairment according to the WHO’s criteria (40). We still found that a ... See full document

... other anti-VEGF ...occurred. Neovascular AMD patients treated with conbercept showed an improvement in BCVA comparable to those treated with other anti-VEGF ... See full document

... 1990’s, treatment options for wet-type AMD were limited and ...several treatment options, which have the possibility to improve or maintain visual acuity for patients suffering from ...The treatment ... See full document

... Mordenti J, Cutherbertson RA, Ferrara N, et al. 1999. Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labelled full-length and Fab antibodies in rhesus monkeys following ... See full document

... Finding the elusive “customized treatment” is not the same as fi nding a new drug, although a long list of new drugs with novel mechanisms of action are being developed. These new interventions will act more ... See full document

... As mentioned earlier, issues of introducing T&E into the clinical practice can be identified in two stages: the patient explanation phase and the operational phase. There were benefits associated with decreased ... See full document

... square analysis showed that the treatment burdensome, low vision rehabilita- tion and daily reading variables provided the least information to the model ... See full document

... reported macular pathologies may be difficult to treat and that some of them are not especially uncommon, having an awareness of a new treatment option and its influence on the clinical course of the ... See full document

... bimonthly treatment regimen with aflibercept was fixed due to the country-specific guideline ...the analysis by including patients with increasing disease ... See full document

... The World Health Assembly in May 2013 adopted a new global programme document entitled “Universal Eye Health: a global action plan 2014-2019” [1]. It states the major priorities for the global prevention of blindness ... See full document

... has risen considerably since the treatment was first in- troduced a decade ago [4, 5]. Elderly people with AMD make up the largest group of patients receiving IVI and the prevalence of the disease increases ... See full document

... Nine sponsor-administered clinical studies, both rando- mized and open-label of 1 to 5 years’ duration, in which subjects received pegaptanib 0.3 mg were included in the analysis. These consisted of all ... See full document

... three treatment arms in Protocol T; however, a post hoc analysis performed demonstrated a statistically significant increased frequency in cardiac and vascular disorders in the ranibizumab ... See full document